Nature - Issue - nature.com science feeds
AI and the human mind: only one is a black box Alfredo Vannacci
Nature, Published online: 07 April 2026; doi:10.1038/d41586-026-01094-7AI and the human mind: only one is a black box
7 April 2026 at 08:00

AI and the human mind: only one is a black box

Nature - Issue - nature.com science feeds

By: Alfredo Vannacci

7 April 2026 at 08:00

Nature, Published online: 07 April 2026; doi:10.1038/d41586-026-01094-7

Nature Medicine
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial Francesca Gay · Wilfried Roeloffzen · Meletios A. Dimopoulos · Laura Rosiñol · Marjolein van der Klift · Roberto Mina · Albert Oriol · Eirini Katodritou · Ka Lung Wu · Paula Rodríguez Otero · Roman Hájek · Elisabetta Antonioli · Mark van Duin · Mattia D’Agostino · Joaquín Martínez-López · Elena M. van Leeuwen-Segarceanu · Elena Zamagni · Niels W. C. J. van de Donk · Katja C. Weisel · Luděk Pour · Jakub Radocha · Angelo Belotti · Fredrik Schjesvold · Joan Bladé · Hermann Einsele · Pieter Sonneveld · Mario Boccadoro · Annemiek Broijl
Nature Medicine, Published online: 06 April 2026; doi:10.1038/s41591-026-04282-0In the phase 3 EMN24 IsKia trial, transplant-eligible patients with newly diagnosed multiple myeloma who received isatuximab with carfilzomib, lenalidomide and dexamethasone pretransplant induction and post-transplant consolidation showed higher rates of measurable residual disease negativity after consolidation than patients who received carfilzomib, lenalidomide and dexamethasone.
6 April 2026 at 08:00

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Nature Medicine

6 April 2026 at 08:00

Nature Medicine, Published online: 06 April 2026; doi:10.1038/s41591-026-04282-0

In the phase 3 EMN24 IsKia trial, transplant-eligible patients with newly diagnosed multiple myeloma who received isatuximab with carfilzomib, lenalidomide and dexamethasone pretransplant induction and post-transplant consolidation showed higher rates of measurable residual disease negativity after consolidation than patients who received carfilzomib, lenalidomide and dexamethasone.

Nature Medicine
An international mega-analysis of psychedelic drug effects on brain circuit function Manesh Girn · Manoj K. Doss · Leor Roseman · Katrin H. Preller · Fernanda Palhano-Fontes · Lorenzo Pasquini · Frederick S. Barrett · Pablo Mallaroni · Natasha L. Mason · Christopher Timmermann · Drummond E. McCulloch · Patrick M. Fisher · Brian S. Winston · Flora Moujaes · Felix Muller · Matthias E. Liechti · Franz X. Vollenweider · Johannes G. Ramaekers · Kim Kuypers · Draulio B. Araujo · Olaf Sporns · Joshua Siegel · Nico Dosenbach · David J. Nutt · Robin L. Carhart-Harris · Emmanuel A. Stamatakis · Danilo Bzdok
Nature Medicine, Published online: 06 April 2026; doi:10.1038/s41591-026-04287-9Analysis of neuroimaging datasets across five major psychedelics revealed a shared brain signature and provides a comprehensive insight into how these drugs reorganize brain architecture.
6 April 2026 at 08:00

An international mega-analysis of psychedelic drug effects on brain circuit function

Nature Medicine

6 April 2026 at 08:00

Nature Medicine, Published online: 06 April 2026; doi:10.1038/s41591-026-04287-9

Analysis of neuroimaging datasets across five major psychedelics revealed a shared brain signature and provides a comprehensive insight into how these drugs reorganize brain architecture.

Normal view